METHODS: Following PRISMA guidelines, a comprehensive literature search was conducted from February to May 2022. Studies in English involving patients undergoing nuclear medicine studies with incidental tumor findings were included. Data on imaging modalities, incidentaloma characteristics, management changes, and follow-up were extracted and analyzed.
RESULTS: Ninety-two studies involving 64.884 patients were included. Incidentalomas were detected in 611 cases (0.9%), with thyroid being the most common site. PET/CT with FDG and choline tracers showed the highest incidentaloma detection rates. Detection of incidentalomas led to a change in therapeutic strategy in 59% of cases. Various radiotracers demonstrated high sensitivity for incidentaloma detection, particularly in neuroendocrine tumors and prostate cancer.
CONCLUSIONS: Nuclear imaging techniques play a crucial role in detecting incidentalomas, leading to significant changes in patient management. The high sensitivity of these modalities highlights their potential in routine oncology follow-up protocols. Future directions may include enhancing spatial resolution and promoting theranostic approaches for improved patient care.
方法:遵循PRISMA指南,从2022年2月至5月进行了全面的文献检索.包括英语研究,涉及接受核医学研究并附带肿瘤发现的患者。成像模式数据,偶发瘤的特点,管理变革,并进行随访分析。
结果:纳入92项研究,涉及64.884例患者。611例(0.9%)检出偶发瘤,甲状腺是最常见的部位。使用FDG和胆碱示踪剂的PET/CT显示出最高的偶发瘤检出率。发现偶发瘤导致59%的病例改变了治疗策略。各种放射性示踪剂对偶发瘤检测表现出高灵敏度,特别是神经内分泌肿瘤和前列腺癌。
结论:核成像技术在检测偶发瘤中起着至关重要的作用,导致患者管理的重大变化。这些模式的高灵敏度凸显了它们在常规肿瘤学随访方案中的潜力。未来的方向可能包括提高空间分辨率和促进治疗方法,以改善患者护理。